Status:
COMPLETED
A Twelve-Week Study of Varenicline for Safety and Efficacy in Comparison With Placebo and Zyban for Smoking Cessation
Lead Sponsor:
Pfizer
Conditions:
Smoking Cessation
Eligibility:
All Genders
18-75 years
Phase:
PHASE3
Brief Summary
The primary purpose of this study is to evaluate the safety and efficacy of varenicline given for a twelve week treatment period in comparison with placebo and Zyban for smoking cessation.
Eligibility Criteria
Inclusion
- Subjects must have smoked an average of at least 10 cigarettes per day during the past year and over the month prior to the screening visit, with no period of abstinence greater than 3 months in the past year.
Exclusion
- Subjects who have used bupropion (Zyban or Wellbutrin) previously.
Key Trial Info
Start Date :
June 1 2003
Trial Type :
INTERVENTIONAL
End Date :
March 1 2005
Estimated Enrollment :
1005 Patients enrolled
Trial Details
Trial ID
NCT00143364
Start Date
June 1 2003
End Date
March 1 2005
Last Update
June 4 2007
Active Locations (15)
Enter a location and click search to find clinical trials sorted by distance.
1
Pfizer Investigational Site
Palo Alto, California, United States
2
Pfizer Investigational Site
San Diego, California, United States
3
Pfizer Investigational Site
Denver, Colorado, United States
4
Pfizer Investigational Site
Pembroke Pines, Florida, United States